L-Ornithine L-Aspartate (LOLA) trials recruiting now
2 registrations that name L-Ornithine L-Aspartate as a study arm and are recruiting or about to, as ClinicalTrials.gov listed them on Oct 20, 2026. Read each listing for its full criteria and current status.
Kymata never assesses eligibility. Each listing names its own criteria; only its study team can say whether someone can join. Trial doses are given under the trial's monitoring and are not a schedule for anyone outside it.
Filter 2 registrations
Status
Phase
All 2 registrations
RecruitingNCT06483737
Human Albumin Infusion in Liver Cirrhosis and Overt Hepatic Encephalopathy (HACHE)
No phase
General Hospital of Shenyang Military Region
About 174 people
Started Jun 24, 2025
In plain words A study of L-Ornithine L-Aspartate in people 18 and older, run by General Hospital of Shenyang Military Region. It plans to enroll about 174 people at 1 site, none in the US.
Who it lists and where
Who the trial lists, as registered
Lists people 18 and older. Conditions: Overt Hepatic Encephalopathy.
A definite diagnosis of liver cirrhosis and overt HE
A serum albumin level of 23-30g/L
Age ≥18 years old
Sign the informed consent
The exclusion criteria are on the listing.
What it tests, as registered
Human albumin infusion at a modified dosage; Human albumin infusion at a routine dosage; Lactulose; Rifaximin; Ornithine Aspartate; Branched-Chain Amino Acids; Arginine
Registered summary
Hepatic encephalopathy (HE), a severe complication of decompensated cirrhosis, is characterized as neurocognitive dysfunction. Emerging evidence suggests the potential role of human albumin infusion for the treatment of HE, but its optimal dosage remains undefined. Therefore, the investigators planned a randomized controlled trial (RCT) to compare the efficacy of human albumin infusion at different dosages in in patients with liver cirrhosis and overt HE.
Where, as registered
No US site; China (1).
RecruitingNCT07117630
An Open-Label, Bayesian Adaptive Phase II Clinical Study in HR+/HER2- Advanced Breast Cancer After Progression on Standard Therapy
Phase 2
Fudan University
About 60 people
Started Sep 25, 2025
In plain words A Phase 2 study of L-Ornithine L-Aspartate in female participants 18 and older, run by Fudan University. It plans to enroll about 60 people at 1 site, none in the US.
Who it lists and where
Who the trial lists, as registered
Lists female participants 18 and older. Conditions: Breast Cancer.
Women aged ≥ 18 years old.
Patients with histologically confirmed HR+/HER2- invasive breast cancer (specific definition: ER > 10% tumor cell positivity by immunohistochemistry is defined as ER positive, PR positive, PR > 10% tumor cell positivity is defined as PR…
Patients with HR+/HER2- advanced breast cancer who have experienced disease progression after receiving systemic therapy including CDK4/6 inhibitors and endocrine therapy.
Patients whom the investigator judges to be suitable for continued endocrine therapy
8 more inclusion criteria and the exclusion criteria are on the listing.
This is a prospective, Phase II, open-label, two-arm parallel study evaluating the efficacy and safety of combined treatment (L-Ornithine L-Aspartate, N-Acetylcysteine) with CDK4/6 inhibitors and Fulvestrant in patients with HR-positive/HER2-negative advanced breast cancer (ABC) who have progressed on prior standard therapy including CDK4/6 inhibitors and endocrine therapy.